Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: A prospective randomized study

Maselli, Guevar; Bergamasco, Luca; Silvestri, Vanuska; Gualá, Luana; Pace, Gianna; Vicentini, Carlo

doi:10.1111/j.1442-2042.2011.02772.x

Cited by 8 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15,16,[19][20][21][22][23][24][25][26][27][28][29][30] To treat REL bladders, experimental approaches will have to move beyond treating early and ensuing responses to PBO. [31][32][33] Indeed, the clinically relevant period available to treat and study this condition is during the post-release phase, 34 once the anatomic obstruction itself has been detected and mitigated. While several reports have described the effect of REL, 23,30,[35][36][37][38][39] the response to targeted pharmacotherapy in the REL period has not systematically combined molecular and functional analyses to find novel relevant candidates.…”

Section: Introductionmentioning

confidence: 99%

Persistent myopathy despite release of partial obstruction: in vivo reversal of dysfunction and transcriptional responses using rapamycin

et al. 2020

View full text Add to dashboard Cite

Current and potential medical therapy for obstruction‐induced myopathic bladder dysfunction (from benign prostatic hyperplasia or posterior urethral valves) focuses on symptoms. The persistent tissue pathology and dysfunction after release of obstruction is often deemed irreversible without any systematic therapeutic approaches. As rapamycin can attenuate bladder smooth muscle hypertrophy and dysfunction during the genesis of partial obstruction in vivo, we tested whether rapamycin could improve persistent function after release of obstruction (de‐obstruction or REL). Female Sprague‐Dawley rat bladders were partially obstructed (PBO) by suturing around both the urethra and a para‐urethral steel rod, then removing the rod. One day prior to release of obstruction (preREL), voiding parameters and residual urine volume of preREL+future rapa, preREL+future veh groups were recorded. Release of obstruction (REL) was performed by suture removal following 6 weeks of PBO. For 4 more weeks after the de‐obstruction, REL animals were randomized to rapamycin (REL+rapa) or vehicle (REL+veh). PBO for 6 weeks were used as positive controls. In shams, the urethra was exposed, but no suture tied. Voiding parameters and residual urine volume were measured prior to sacrifice of sham and REL+veh or REL+rapa, and PBO. Rapamycin efficacy was tested by pair‐wise comparison of changes in individual voiding data from preREL+future veh or preREL+future rapa versus REL+veh or REL+rapa, respectively, as well as by comparisons of REL+veh to REL+rapa groups. Bladders were weighed and processed for a high‐throughput QPCR array, and histopathology. Bladder/body mass ratios with PBO increased significantly and remained higher in the release phase in REL+veh animals. REL+rapa versus REL+veh improved residual volumes and micturition fractions toward sham levels. Three genes encoding extracellular proteins, BMP2, SOD3, and IGFBP7, correlated with functional improvement by Pearson's correlations. The promoters of these genes showed enrichment for several motifs including circadian E‐boxes. While obstruction and REL augmented CLOCK and NPAS2 expression above sham levels, rapamycin treatment during release significantly blocked their expression. This experimental design of pharmaco‐intervention during the de‐obstruction phase revealed a novel pathway dysregulated during the clinically relevant treatment phase of obstructive bladder myopathy.

show abstract

Section: Introductionmentioning

confidence: 99%

Persistent myopathy despite release of partial obstruction: in vivo reversal of dysfunction and transcriptional responses using rapamycin

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the present study, anticholinergic drug use was a predictor of IPSS improvement. The IPSS may be decreased in patients taking anticholinergic drugs because PDE5i have therapeutic potential in the treatment of overactive bladder (OAB) symptoms .…”

Section: Discussionmentioning

confidence: 99%

Penile blood pressure is useful to identify candidates for tadalafil treatment in patients with lower urinary tract symptoms

Koyama¹,

Kaiho

Kawasaki

et al. 2018

BJU International

View full text Add to dashboard Cite

show abstract

“…As a consequence of this, it is generally accepted that the structure and functions of the bladder are more complex than previously thought. Many laboratories are describing and characterising new cell types, among them, the interstitial cells 47,48,77 and neural networks 78 . The interstitial cells all play a role in the complex physiological and pathological events.…”

Section: Peripheral Controlmentioning

confidence: 99%

“…Unfortunately, no studies have been published on this potentially important relationship. By contrast, PGE 2 has been assessed as a treatment for bladder hypocontractility or underactive detrusor syndromes, although little clinical benefit was observed 77,78 . Even in combination with the cholinergic agonist bethanechol chloride, intravesical instillation of PGE 2 had only limited therapeutic benefit compared to placebo 79 .…”

Section: Pharmacological Interventionmentioning

confidence: 99%

“…Despite agreement in the literature that prostanoids have an important role in bladder physiology, approaches that target these factors (by modulating prostanoid receptors, inducing prostanoid synthesis or administering exogenous prostanoids) have failed to gain a place in the standard therapeutic arsenal for functional bladder disorders. This failure is partly attribut able to the high incidence of adverse effects associated with the medications used and, in some cases, to their poor clinical effi cacy [73][74][75][77][78][79]81,82 . Despite these setbacks, efforts to find effective prostanoid-based strategies to treat bladder disorders are ongoing.…”

Section: Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Prostaglandins and Phosphodiesterases in the urinary bladder wall

Rahnama’i¹

View full text Add to dashboard Cite

People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.• The final author version and the galley proof are versions of the publication after peer review.• The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

show abstract

Tadalafil versus solifenacin for persistent storage symptoms after prostate surgery in patients with erectile dysfunction: A prospective randomized study

Cited by 8 publications

References 32 publications

Persistent myopathy despite release of partial obstruction: in vivo reversal of dysfunction and transcriptional responses using rapamycin

Persistent myopathy despite release of partial obstruction: in vivo reversal of dysfunction and transcriptional responses using rapamycin

Penile blood pressure is useful to identify candidates for tadalafil treatment in patients with lower urinary tract symptoms

Prostaglandins and Phosphodiesterases in the urinary bladder wall

Contact Info

Product

Resources

About